Klaria’s CEO Jesper Wiklund has acquired shares in Klaria today
Klaria’s CEO Jesper Wiklund today, Wednesday March 24th, 2021 acquired shares in Klaria Pharma.
The trades were made on NASDAQ Frist North. Jesper Wiklund acquired 41,483 shares at an average price of SEK 6.87 for a total purchase of ca 285,000 SEK.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.